←
Edwin Posadas, MD673 posts
Edwin Posadas, MD avatar✓

Edwin Posadas, MD ✓

@EdwinPosadasMD

Director,Cancer Therapeutics Program; Medical Director, Center for Uro-Oncology Research Excellence (CURE) - Cedars-Sinai-Cancer

◷ Joined April 2013▧ 168 Photos and videos
Ravi A Madan M.D. avatar
⟳ Edwin Posadas, MD retweeted
Ravi A Madan M.D.@Dr_RaviMadan·Feb 26

As we get ready for the update on the overall survival in #BRCAAway trial @asco #GU26 It is worth noting the small number of patients that’s crossed over. In that context this data has its limits in comparing combination vs sequence in #ProstateCancer

Post attachment
Jun Gong, MD avatar
⟳ Edwin Posadas, MD retweeted
Jun Gong, MD@jgong15·Feb 26

@AmarUKishan POSEIDON meta-analysis of 6 PhIII RCTs on hormonal therapy (HT) after post-op RT (PORT) in localized #Prostatecancer ➡️ no OS benefit w/HT to PORT & no significant interaction b/t duration of HT & this effect (p-interaction 0.25) for PSA<0.5 #GU26 @OncoAlert

Post attachmentPost attachmentPost attachmentPost attachment
Ravi A Madan M.D. avatar
⟳ Edwin Posadas, MD retweeted
Ravi A Madan M.D.@Dr_RaviMadan·Feb 26

#BRCAaway OS data presented by Dr. Maha Hussein #GU26 @asco Launched prior to large phase 3s in #ProstateCancer Cancer Provocative data but as Dr Hussein acknowledges small numbers in cross over (8 patients) limits ability to truly understand sequencing vs combo

Post attachmentPost attachmentPost attachment